Background: Radiation at doses high enough to cure cancer also frequently destroys normal tissue. Development of agents that protect normal tissue without also protecting diseased tissue has been difficult. In vivo radioprotection of bone marrow by acidic and basic fibroblast growth factors (FGF! and FGF 2 , respectively) has recently been demonstrated after whole-body irradiation of C3H/HeN mice. Purpose: Our purpose was to determine whether myeloprotective doses of those growth factors also protect malignant tumors. Methods: First, we investigated the effects of exogenous FGFj or FGF 2 (FGF!/ 2 ) administration (treatment group receiving two intravenous injections of 3 (ig FGFj/2 per mouse 24 hours and 4 hours before local irradiation of right hind leg and control group receiving two intravenous injections of 0.1 mL of saline) on growth and radiosensitivity of three transplantable murine tumors (one squamous cell carcinoma [SCC-VII] and two sarcomas [KHT and Rif-1]), all of which were grown in C3H/HeN mice. We then evaluated the effect of FGF 1/2 on tumor cell proliferation, cell cycle distribution, and pulmonary metastatic frequency in the mice. Specifically, survival studies were performed in mice treated with 0, 6, 6.5, 7.5, 8.5, 9, or 10 Gy whole-body irradiation with or without FGF 2 (n = 250). Rif-1 (n = 40), KHT (n = 40), and SCC-VII (n = 40) tumors were implanted in the hind leg of mice, and mice were treated with FGF 2 or saline when their tumorbearing thighs were 9 mm in diameter. In separate experiments (treatment group receiving two injections of 3 |ig
Background: Radiation at doses high enough to cure cancer also frequently destroys normal tissue. Development of agents that protect normal tissue without also protecting diseased tissue has been difficult. In vivo radioprotection of bone marrow by acidic and basic fibroblast growth factors (FGF! and FGF 2 , respectively) has recently been demonstrated after whole-body irradiation of C3H/HeN mice. Purpose: Our purpose was to determine whether myeloprotective doses of those growth factors also protect malignant tumors. Methods: First, we investigated the effects of exogenous FGFj or FGF 2 (FGF!/ 2 ) administration (treatment group receiving two intravenous injections of 3 (ig FGFj/2 per mouse 24 hours and 4 hours before local irradiation of right hind leg and control group receiving two intravenous injections of 0.1 mL of saline) on growth and radiosensitivity of three transplantable murine tumors (one squamous cell carcinoma [SCC-VII] and two sarcomas [KHT and Rif-1]), all of which were grown in C3H/HeN mice. We then evaluated the effect of FGF 1/2 on tumor cell proliferation, cell cycle distribution, and pulmonary metastatic frequency in the mice. Specifically, survival studies were performed in mice treated with 0, 6, 6.5, 7.5, 8.5, 9, or 10 Gy whole-body irradiation with or without FGF 2 (n = 250). Rif-1 (n = 40), KHT (n = 40), and SCC-VII (n = 40) tumors were implanted in the hind leg of mice, and mice were treated with FGF 2 or saline when their tumorbearing thighs were 9 mm in diameter. In separate experiments (treatment group receiving two injections of 3 |ig each of FGF 2 [6 jug total] either intravenously or intratumorally 24 hours and 4 hours before local tumor irradiation and control group receiving 0.1 mL saline), tumor growth was followed, and mice were killed to count lung metastases and measure tumor proliferating cell nuclear antigen (PCNA) and bromodeoxyuridine labeling at various times thereafter (three to eight mice per group). Tumor growth curves of untreated and irradiated tumors were determined with and without intravenous or intratumoral FGFj/z in SCC-VII tumors (n = 120). Radiation doses to the tumor-bearing leg were 15 Acidic fibroblast growth factor (FGF|) and basic fibroblast growth factor (FGF 2 ) are cytokines produced by numerous cells . One of their diverse properties is protection against chemotherapy-and radiation-induced bone marrow toxicity in vitro (4, 5) . More recently, we found that FGF) and FGF 2 are both radioprotectors of bone marrow in whole-body irradiation studies in C3H and BALB/c mice (6,7). Some reports (8,9) also suggest that FGF 2 can radioprotect the lung, although not all reports agree (70). The exact mechanisms of in vivo FGF]-and FGF 2 -mediated radioprotection are yet unknown. These factors may induce hematopoietic cell proliferation, may suppress apoptosis (programmed cell death), or may directly alter the intrinsic radiosensitivity of bone marrow progenitor cells (6, 11 ). An effective dose, treatment schedule, and route of administration of FGF, or FGF 2 (FGF 1/2 ) must be used to ensure response (6). Studies from our research team have shown that the near-optimal dose is 6 |ig FGF 2 per mouse or 12 |ig FGF] per mouse given intravenously. The dose is split; half is given 24 hours and the other half is given 4 hours before whole-body irradiation. Unlike more classic electron-scavenging radioprotectors, some radioprotection is detected even if FGFi^ injections are given 24 hours after radiation.
It is unknown whether radioprotective doses of FGF 1/2 are sufficient to also produce such deleterious effects as promotion of tumor growth, induction of lung metastasis, or alteration of tumor radiosensitivity. For example, FGF 2 reduces radiation-induced capillary endothelial cell apoptosis detected by an immunohistochemical assay (9) . This radioprotection of vascular endothelium could be advantageous for tumor growth. It is also well established that, as a rule, highly angiogenic tumors are more aggressive than tumors with less angiogenesis. Hence, there is reason for concern that therapy with FGF 1/2 could have hazardous side effects.
The present study was conducted to determine whether myeloprotective doses of these growth factors also protect malignant tumors.
Materials and Methods

Overall Approach
We investigated the effects of exogenous administration (24 and 4 hours before irradiation) on the growth and radiosensitivity of three transplantable murine tumors (one squamous cell carcinoma and two sarcomas) grown in C3H/HeN mice. We evaluated the effects of FGF ]/2 on the growth rate of the primary tumor, tumor cell proliferation, cell cycle distribution, and frequency of pulmonary metastases.
Mice
Female C3H/HeN mice were supplied through the Animal Production Unit of the National Cancer Institute-Frederick Cancer Research and Development Center (Frederick, MD). They were maintained in the Research Animal Facility of the National Institutes of Health and were housed in conventional polycarbonate cages (five mice per cage). Animal rooms were climate controlled (temperature and humidity) and circadian rhythm adjusted (12 hours' light and 12 hours' darkness). All mice were 7-10 weeks old at the time of tumor transplantation. Eight-week-old mice were used for whole-body irradiation studies. The experiments were approved by the National Cancer Institute Institutional Animal Care and Use Committee.
Transplantation of Tumors
The following three murine tumors syngeneic to C3H/HeN mice were used in these experiments: one squamous cell carcinoma (SCC-VII) and two sarcomas (KHT and Rif-1). Single-cell suspensions of excised tumors were prepared as described previously (12) . The cell viability, evaluated by trypan blue dye exclusion, was greater than 85% for each type of tumor. We injected 5x10 tumor cells from each cell line (Rif-1 [n = 40], KHT [n = 40], and SCC-VII [n = 40]) intramuscularly into the right hind thigh of the mice. When their tumor-bearing thighs were 9 mm in diameter, the mice were divided into two groups. One group received two intravenous injections of 3 ng FGF 2 each; the first injection was given 24 hours and the second was given 4 hours before local leg irradiation. The other group was given two intravenous injections of 0.1 mL saline as controls. After FGF 2 administration, the tumor-bearing leg was irradiated locally. Tumor size was recorded three times per week until the tumors were around 20 mm in diameter. There were 10 animals per group. In a separate experiment, the mice with the SCC-VII tumor were given either intravenously or intratumorally two injections of 3 ng FGF|/2 each (6 u.g total) 24 and 4 hours before local tumor irradiation (n = 120). with the control group receiving 0.1 mL saline. In all tumor growth experiments, there were 10 animals per group.
Cytokine Administration
Human recombinant FGF ]/2 was purchased from Pepro Tech Inc., Rocky Hill. NJ. Both FGF, (lot No. 3315) and FGF 2 (lot No. 3412) had a concentration of 1 mg/mL in H,O (pH 7.4). The desired dose of FGF,ŵ as administered intravenously in a final volume of 0.1 mL per injection as previously described (6). Control mice received the same volume of saline.
Irradiation
In the whole-body irradiation survival study, groups of 10 or 20 mice were placed in a Plexiglas container(s) and were irradiated up to a total dose of 6, 6.5, 7.5, 8.5, 9, or 10 Gy with a 137 Cs gamma cell 40 (Nordion International, Inc., Kanata, ON, Canada) (n = 250). The irradiator was calibrated with the use of thermoluminescent dosimetry chips implanted in wax mouse phantoms as previously described (6). This irradiator had a dose rate of approximately 1 Gy per minute.
In tumor radiation-response studies, the tumorbearing leg of the mouse under air-breathing conditions was locally irradiated with the use of a 9-MeV electron field. The unanesthetized mice were immobilized in a specially designed jig, which allowed the tumor-bearing leg to be centered over a window, with the lead shield protecting the remainder of the animal. The radiation doses used were 30 Gy for Rif-1, 15 Gy for KHT, and 15 and 30 Gy for SCC-VII tumors. The dose rate was approximately 10 Gy per minute.
Histologic Analysis of Lung Metastases From Tumor-Bearing Mice
Mice were periodically killed after FGF 1/2 treatment and irradiation. Their primary tumors, lungs, liver, spleen, and kidneys were excised immediately and placed in 10% neutral buffered formalin. Fixed tissues were embedded in paraffin blocks, from which 4-u.m serial sections were cut and stained with hematoxylin-eosin. The number of metastatic foci in whole lungs was determined by microscopic examination and scored from each animal group (three to eight mice per group).
Immunohistochemical Staining of Proliferating Cell Nuclear Antigen and FGF Receptor-1
Immunohistochemical analysis was performed with the use of a modified avidin-biotinylated peroxidase technique contained in Vectastain kits (Vector Laboratories, Inc., Burlingame, CA). Three serial sections of each tumor were stained with hematoxylin-eosin, and two were stained with antiproliferating cell nuclear antigen (PCNA) or anti-FGF receptor-1 antibody. Two observers independently evaluated the results. The PCNA-labeling index was determined with the use of monoclonal antibody for PCNA (Oncor, Inc., Gaithersburg, MD). Assays were performed 3, 6, and 8 days after the second FGF 2 dose. The numbers of PCNAlabeled cells were scored by counting 20 random, high-power fields (lOOOx) from each tumor sample (three tumor samples per group) and are presented as PCNA-positive cells per high-power field. Polyclonal FGF receptor-1 antibodies (Ab-1) were purchased from Oncogene Science, Inc., Cambridge, MA, and were used in a 5-jlg/mL concentration. Tumors used for PCNA on day 3 were also used for bromodeoxyuridine (BrdUrd) flow cytometry.
Flow Cytometry
Two hours before their tumors were resected, the mice were given 1 mg BrdUrd intraperitoneally. Upon resection, the primary rumors were cut into pieces of 2-3 mm, and a single-cell digestion was made as described previously (13) 
, Mountain View, CA) for 1 hour at room temperature. Cells were washed once with PBS with 0.1% Triton X-100 and incubated with 20 Jig of a fluorescein isothiocyanate-linked anti-mouse immunoglobulin G secondary antibody (Sigma Chemical Co., St. Louis, MO) for 45 minutes at room temperature. The cells were then washed and incubated with 10 |lg/mL propidium iodide (Sigma Chemical Co.) to label the total DNA. All samples were processed with the use of an Epics V cell sorter (Coulter Electronics, Inc., Hialeah, FL). Both the fluorescein isothiocyanate secondary antibody and the propidium iodide were excited with the 488-nm line of the argon ion laser, and the cellular fluorescence between 518-532 nm (BrdUrd) and greater than 630 nm (propidium iodide) was detected as described previously (13) . There were three tumor samples per group; these were the same three tumors used for determining the PCNA-labeling index.
Statistics
For each experiment, the mean (±1 standard error) was calculated from data obtained from three to 20 mice. Two-tailed Student's t test, chi-squared test, or Fisher's exact test was used, whichever was appropriate (14) .
Results
Percent survival and median survival time after whole-body irradiation are shown in Table 1 . In the absence of FGF 2 , 90%-95% of mice receiving 850 cGy whole-body irradiation died; the median survival time was 15 days. This outcome was not significantly improved by the administration of 1 (ig FGF2 per mouse before whole-body irradiation (15% for FGF 2 versus 5% for saline; />>.05). A 6-| 0.g split course of FGF2 (3 \ig each course) given 24 hours and 4 hours before whole-body irradiation, however, resulted in a 95% survival 45 days after 850 cGy (P<.001 fchi-squared test]).
The effect of intravenous FGF 2 on the growth of the three murine tumors was examined in C3H/HeN mice. Tumor growth kinetics are shown in Fig. 1 , and growth end points are given in Table 2 . The two fastest growing tumors, KHT and SCC-VII, reached 23 mm 8 days after FGF 2 treatment, whereas the Rif-1 tumor grew to approximately the same size 15 days after FGF 2 administration. There was, however, no statistically significant difference in tumor growth rate or tumor size between the saline-treated and FGF 2 -treated animals (Fig. 1) . This was also *Median survival and survival at 45 days after whole-body irradiation in saline-or FGF2-treated mice. A minimum of 10 mice was studied per group. Radiation doses ranged from 6.0 to 10.0 Gy. FGF2 improved survival of mice when a total dose of 6 ug was given 24 and 4 hours before irradiation.
tSmaller control group than test group.
%P<.00\ (chi-squared test).
true when tumor growth was assessed as tumor weight at day 8 after FGF2 treatment.
In the same experiment, the effect of FGF 2 on tumor metastases in the lungs was also determined. KHT and SCC-VII tumor-bearing mice were killed on day 2, 4, or 8 after FGF 2 injection, and Rif-1 tumor-bearing mice were killed on day 4, 8, or 15 after FGF 2 injection. Table 2 indicates the frequency of lung metastases for each tumor type. FGF 2 had no detectable effect on the number of metastatic lung foci.
Both BrdUrd and PCNA techniques were used to estimate the cell proliferation rate of these three murine tumors before and after FGF 2 treatment. Intravenous FGF 2 treatment did not alter the tumor cell cycle distribution or the Sphase fraction as compared with the findings for saline-treated control mice measured 3 days after the first FGF 2 dose. Likewise, FGF 2 did not alter the PCNAlabeling index (Fig. 2) .
The radiosensitivity of all three tumor types pretreated with FGF^ was also determined. There was no difference in either tumor size or tumor growth delay when intravenous FGF 2 was given, as shown in Fig. 1 . For KHT or SCC-VII tumors, local irradiation with 15 Gy was insufficient to cause a tumor growth delay, and FGF 2 did not enhance the minimal response. In other experiments, we implanted SCC-VII tumors in C3H/HeN mice and administered the usual split course of 6 |ig (3 ng at 24 hours and 3 |ig at 4 hours) FGF 1/2 intravenously or intratumorally prior to local irradiation with 30 Gy. Growth rate and radiation response were recorded and are shown in Fig. 1 . Intratumoral, but not intravenous, injection of FGFi^ caused an increase in the size of SCC-VII tumors. Although the difference was modest, it became statistically significant (P<.05 [Student's t test]) 3 days after FGF^ treatment and remained so even when normalized for the small difference (if any) between groups on the day of FGF 1/2 injection. When radiation was given following FGF 1/2 , however, the response was at least as good as that of the control mice (Fig. 1) . Discussion FGF 2 is a radioprotector of both endothelial and hematopoietic cells in murine systems in vivo {6,9). An optimal FGF 2 dose and administration schedule are required to obtain the maximum radioprotective effect. A dose of 1 |ig FGF 2 per mouse given before wholebody irradiation resulted in no survival advantage relative to that of the control mice (15% versus 5%; P>.05). However, 6 fig FGF 2 given in two 3-(ig fractions provided effective radioprotection in C3H/HeN mice. The findings indicate that there may be a threshold level of FGF 1/2 below which the radioprotective effect is not apparent and that doses greater than "optimum" are of no advantage. Recently, we (6) showed that FGF 2 protects animals receiving known lethal radiation doses through a mechanism that includes promotion of hematopoietic recovery. This recovery may be due to increased repopulation (6), a modulation of hematopoietic cytokine production in the bone marrow stroma (75), or an alteration of the intrinsic radiosensitivity of bone marrow (77). Both in vitro and in vivo studies support these observations. FGF) and/or FGF 2 can be clinically useful only if they are not simultaneously protecting bone marrow and tumor. A few studies report on the proliferative effects of exogenous cytokines on murine tumor growth. Using another hematopoietic radioprotective cytokine, interleukin 1 (IL-1), Dorie et al. intravenously) did not change the growth rate of three murine tumors and did not alter the number of lung metastases, Sphase fraction, or PCNA-labeling index.
With the use of our most myeloprotective treatment schedule, intravenous FGF 2 did not shorten the radiation-induced tumor growth delay. In contrast, intratumoral injection of FGF|/2 produced a small but statistically significant increase in the size of the SCC-VII tumor, suggesting there is a dose response to the FGF|/2 effects. The radiation response of tumors after intratumoral FGF 2 was comparable to that of tumors in control animals. Since unirradiated tumors would have been larger than those of the controls after intratumoral FGF 2 , the results suggest that FGF 2 mildly enhanced radiosensitivity. Endothelial cell proliferation induced by FGF 2 may help the oxygenation of SCC-VII tumors, resulting in an improved radiation response for tumors with high hypoxic cell fractions. Two studies support this hypothesis. First, Leith et al. (79) reporting on a colon adenocarcinoma of human origin observed that FGF 2 administration (0.25 mg/kg per day for 7 days), at a dose 10-fold greater than that needed to maximally protect bone marrow, increased tumor growth rate but decreased the hypoxic cell component (42.9% versus 19.1%). In another study, Gross et al. (20) demonstrated that tumors respond differently, depending on their FGF 2 receptor and protein levels. C6 glioma tumors had high FGF 2 receptor and protein levels and did not respond to exogenous FGF 2 but grew more slowly when given blocking antibody. In contrast, DLD-2 colon adenocarcinomas had perivascular FGF receptor-1 expression *Intramuscular leg tumor size and metastatic frequency were measured. Three tumor types in C3H/HeN mice were used, and assays were performed at multiple times after FGF2 treatment. A total FGF2 dose of 6 ug was given in two equally divided intravenous doses when leg diameters were 9 mm (day 0). None of the Rif-1 tumors had any detectable metastasis. Days After FGF2 Injection Fig. 2 . Immunohistochemical labeling of proliferating cell nuclear antigen (PCNA) was performed at multiple times after treatment of tumor-bearing C3H/HeN mice with basic fibroblast growth factor (FGF2) (total 6 ug given intravenously [IV] in two equally divided doses when thigh diameters were 9 mm). There was no evidence of increased PCNA-labeling index in FGF2-treated mice for the three murine tumors tested. Assays were performed 3. 6, and 8 days after the second FGF2 dose. Bromodeoxyuridine flow cytometry was performed on the same animals used for determining the PCNA-labeling index. There were three tumor samples per group.
We will examine this physiologic effect directly in the future. In summary, intravenous administration of a minimum of 6 |J.g FGF 1/2 per mouse (3 |ig at 24 hours and 3 fig at 4 hours before whole-body irradiation) significantly protected C3H/HeN mice from lethal irradiation. The same dose and administration schedule of FGFj/ 2 given intravenously did not result in a significant tumor growth stimulation or in an increase in pulmonary metastases relative to the control mice. An absence of obvious tumor growth rate alteration was associated with an absence of cell cycle distribution change and a stable tumor cell PCNA labeling. Direct intratumoral injection of FGF 2 did cause a modest increase in tumor growth rate, but radiation response was unperturbed. Our results with the use of intravenous administration of FGF[y 2 at a myeloprotective dose and dose schedule suggest that FGFi/ 2 does not simultaneously alter tumor aggressiveness. These results lay the groundwork for the feasibility of ¥GF m use in a clinical radiation therapy setting.
